Alma Bio Therapeutics presented in the biotech session of the special webinar “Bouncing back from the crisis. How to re-establish partnerships between Israel and the
January 2021 – Alma Bio Therapeutics attended the 4th Antigen Specific Immune Tolerance digital event.
September 2020 – Prof. Francisco Javier Quintana of Brigham and Women’s Hospital Harvard Medical School, a world-renowned expert in immune regulation and tolerance, joins Alma’s
July 2020 – Alma Bio Therapeutics was among the recipients of PGE, the French government state guaranteed loan.
March 2020 – Alma Bio Therapeutics participated at Digital BioEurope Spring
March 2020 – Alma Bio Theraeutics presented at the RESI Digital partnering event
December 2019 – Alma Bio Therapeutics will be attending the French-Israeli joint event in the healthcare sector, Paris December 10, 2019, sponsored by the BPI, the
December 2019 – Alma has been invited to present at the EIT Health Summit 2019, December 2-3 Paris. Come and meet us there.
October 2019 – Alma receives the EMA’s CHMP (Committee for Medicinal Products for Human Use) scientific advice. The Agency’s advice concerned quality development, pre-clinical development
August 2019 – Alma is featured in Cello Health BioConsulting’s “Next-generation-therapies-for-autoimmune-and-inflammatory-diseases”. Alma is listed among the “next generation approaches in development with novel targets and
January 2019 – Alma appointed Dr. Alain P. Rolland to serve on its scientific advisory board. Dr. Rolland’s appointment will strengthen Alma’s capacities in the
Dr Binah Baum, Alma Bio Therapeutics CEO, was at the Health Investor Day in Paris on June 24th-25th, 2019.
We were at the 37th annual JP Morgan Healthcare Investor Conference in San Francisco, CA from January 7th-10th, 2019
Dr Binah Baum, Alma Bio Therapeutics CEO, was at Biofit 2018 in Lille, from December 3rd-5th, 2018